Norris Medicines Ltd (NORRIS) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Norris Medicines Ltd on NSE and BSE, with an AI summary of each filing.
Scrutinizer''s Report and Voting Results of the 35th Annual General Meeting of the Company held on Tuesday 29th September, 2026
Annual General Meeting · 30 Sept 2026, 12:26 am
Scrutinizer''s Report and Voting Results of the 35th Annual General Meeting of the Company held on Tuesday 29th September, 2026
Annual General Meeting · 30 Sept 2026, 12:22 am
Outcome and proceeding of the 35th Annual General Meeting of the Company held on Tuesday 29th September, 2026
Annual General Meeting · 29 Sept 2026, 11:03 pm
Outcome and proceeding of the 35th Annual General Meeting of the Company held on Tuesday 29th September, 2026
Annual General Meeting · 29 Sept 2026, 10:59 pm
Outcome of 35th Annual General Meeting of the Company held on Tuesday, 29th September, 2026
Annual General Meeting · 29 Sept 2026, 10:56 pm
Annual Report of the Company for the Financial year 2025-26.
Others (Uncategorized) · 05 Sept 2026, 1:27 am
Notice of 35th Annual General Meeting of the Company for the Financial Year 2025-26
Annual General Meeting · 05 Sept 2026, 1:19 am
Outcome of the Board Meeting on Thursday, 03rd September, 2026 pursuant to Regulation 30 of the SEBI(LODR) Regulations, 2015
Others (Uncategorized) · 04 Sept 2026, 12:02 am
Norris Medicines Board Approves FY26 Annual Report and 35th AGM Schedule On 3rd Sep'26, Norris Medicines Limited approved its FY26 Annual Report and Directors' Report. The Board scheduled the 35th AGM for 29th Sep'26 via video conferencing, approving the corresponding book closure and e-voting cut-off dates. Additionally, Purva Sharegistry was appointed to facilitate the e-voting process, with Hemant Shetye designated as the scrutinizer to ensure fair and transparent proceedings.
Appointment of Mr. Vimal Dhirendra Shah (DIN: 01506655) as a Managing Director (Promoter and Executive) of the Company for a term of 3 (Three) consecutive years effective from 1st September, ....
Change in Management · 14 Aug 2026, 11:04 pm
Norris Medicines Q1FY27 Results and MD Re-appointment Norris Medicines reported a net loss of ₹39.68 lakh for Q1FY27, widening from a ₹31.04 lakh loss YoY. Revenue from operations declined 36.5% YoY to ₹92.49 lakh. Total expenses decreased to ₹132.17 lakh from ₹179.08 lakh YoY. EPS stood at -₹0.40 versus -₹0.31 in the prior year's quarter. The Board also approved the re-appointment of Mr. Vimal Dhirendra Shah as Managing Director for a three-year term, effective from 01 Sep'26, subject to shareholder approval.
Financial Results for the Quarter ended June 30,2026
Financial Result · 14 Aug 2026, 10:56 pm
Norris Medicines Ltd - Financial Result for the Quarter ended 30th Jun'26 (Standalone, INR Lakhs) ■ Revenue: 92.5 (-36.5% YoY | -34.3% QoQ) ■ EBITDA: -28.2 (-181.3% YoY | Profit to Loss QoQ) ■ EBITDA Margin (%): -30.5 (-2360 bps YoY | Profit to Loss QoQ) ■ PAT: -39.7 (-27.8% YoY | Profit to Loss QoQ) ■ EPS (INR): -0.40 (-29.0% YoY | Profit to Loss QoQ)
Board Meeting held on August 14, 2026 for the quarter ended June 30, 2026.
Outcome · 14 Aug 2026, 10:48 pm
Norris Medicines Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2026 ,inter alia, to consider and approve Unaudited Financial Results ....
Intimation · 14 Aug 2026, 5:30 am
Norris Medicines Board Meeting Set to Approve Q1FY27 Results Norris Medicines Ltd. (BSE: 524414) has scheduled a Board of Directors meeting on 14th Aug'26 to consider and approve the un-audited financial results for the quarter ended 30th Jun'26. In accordance with SEBI regulations, the trading window for dealing in the company's securities has been closed from 01st Jul'26 and will reopen 48 hours after the financial results are declared to the stock exchange.
Intimation relating to appointment of Mr. Iqubal Ismail Patel as Chief Financial Officer (CFO) & Key Managerial Personnel (KMP) of the Company in the meeting of the Board dated 30th July, 2026.
Change in Management · 30 Jul 2026, 11:56 pm
Norris Medicines Appoints Iqubal Ismail Patel as New CFO Norris Medicines Limited has appointed Mr. Iqubal Ismail Patel as Chief Financial Officer (CFO) and Key Managerial Personnel, effective 30th Jul'26. Mr. Patel is an internal candidate with over 11 years of experience at the company, holding significant roles in finance, accounts, taxation, and strategic financial operations. He is a graduate and is not related to any directors or existing Key Managerial Personnel. The appointment follows the recommendation of the Audit and Nomination & Remuneration Committees.
Outcome of Board Meeting held on Thursday, July 30, 2026 pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Others (Uncategorized) · 30 Jul 2026, 11:47 pm
Norris Medicines Appoints Mr. Iqubal Ismail Patel as New CFO Norris Medicines has appointed Mr. Iqubal Ismail Patel as its new Chief Financial Officer (CFO) and Key Managerial Personnel, effective 30th Jul'26. Mr. Patel, an internal candidate, has been with the company for over 11 years, possessing extensive experience in finance, accounting, taxation, and financial planning. He holds a Graduate degree and is not related to any existing Directors or Key Managerial Personnel. The appointment was approved by the Board of Directors on the recommendation of the Audit and Nomination committees.
Certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations 2018 for the quarter ended 30 June, 2026.
Others (Uncategorized) · 03 Jul 2026, 8:36 pm
Norris Medicines Submits Compliance Certificate for Dematerialization Norris Medicines Limited has filed its compliance certificate under SEBI Regulation 74(5) for the quarter ended 30 Jun'26. The certificate, issued by Registrar and Transfer Agent Purva Sharegistry, confirms the timely processing of all dematerialization requests received from depository participants. It also verifies that securities certificates were appropriately cancelled and mutilated after dematerialization, with depository names updated in the register of members. This filing confirms procedural compliance for the quarter.
Appointment of Internal Auditor w.e.f 30.05.2026
Change in Management · 30 May 2026, 10:15 pm
Norris Medicines Reports FY26 Results and Appoints New Internal Auditor Norris Medicines reported Q4 FY26 results, posting a Profit After Tax of ₹5.06 lakhs compared to a loss of ₹22.85 lakhs YoY. Revenue from operations for the quarter stood at ₹140.84 lakhs, a significant decline from ₹272.09 lakhs YoY. For the full year FY26, the company recorded a net loss of ₹28.06 lakhs versus a loss of ₹123.75 lakhs in FY25, on revenues of ₹813.20 lakhs. The Board also approved the appointment of M/s. Dhiren Y Parikh & Co. as Internal Auditors for FY27.
As per attachment.
Financial Result · 30 May 2026, 9:56 pm
Norris Medicines Reports Q4 FY26 Results & Appoints New Internal Auditor Norris Medicines reported Q4 FY26 results on 30 May'26, posting a profit after tax of ₹5.06 lakhs versus a loss of ₹22.85 lakhs YoY. Revenue from operations for the quarter stood at ₹140.84 lakhs, a significant decrease from ₹272.09 lakhs YoY. For the full year FY26, the company recorded a net loss of ₹28.06 lakhs on revenue of ₹813.20 lakhs. The Board also approved the appointment of M/s. Dhiren Y Parikh & Co. as the Internal Auditors for FY27.
As per attachment.
Outcome · 30 May 2026, 9:47 pm
Norris Medicines Ltd - Financial Result for the Quarter ended 31st Mar'26 (Standalone, INR Lakh) ■ Revenue: 141 (-48.2% YoY | -56.9% QoQ) ■ EBITDA: 30.8 (+336.3% YoY | -67.5% QoQ) ■ EBITDA Margin (%): 21.8 (+1925 bps YoY | -711 bps QoQ) ■ PAT: 5.1 (Loss to Profit YoY | -92.7% QoQ) ■ EPS (INR): 0.05 (Loss to Profit YoY | -92.9% QoQ)
Norris Medicines Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2026 ,inter alia, to consider and approve As per attachment.
Intimation · 30 May 2026, 5:30 am
Norris Medicines Board Meeting Set for Audited FY26 Results Norris Medicines Limited (BSE: 524414) has scheduled a Board of Directors meeting on 30th May'26. The primary agenda is to consider and approve the audited financial results for the quarter and year ended 31st Mar'26. This includes the Audit Report, Cash Flow Statement, and Statement of Asset and Liability. The trading window for insiders has been closed since 01st Apr'26 and will reopen 48 hours after the results are declared, in compliance with SEBI regulations.
As per attachment.
Financial Result · 14 Feb 2026, 10:11 pm
Norris Medicines Reports Profitable Q3 FY26 Results, Reversing Prior Losses Norris Medicines announced Q3 FY26 results, posting a profit after tax of ₹69.74 lakhs for the quarter ending 31 Dec'25. This marks a significant turnaround from the ₹71.82 lakh loss in the prior quarter and a ₹28.17 lakh loss in the same quarter last year. Revenue from operations grew 195% YoY to ₹326.66 lakhs. For the nine months ended 31 Dec'25, the company narrowed its net loss to ₹33.12 lakhs from a loss of ₹100.90 lakhs YoY, driven by a 117% rise in revenue.
As per attachment
Outcome · 14 Feb 2026, 10:04 pm
NORRIS MEDICINES LIMITED - Financial Result for the Quarter ended 31st Dec'25 (Standalone, INR Lakhs) ■ Revenue: 327 (+195.4% YoY | +63.3% QoQ) ■ EBITDA: 94.6 (Loss to Profit YoY | Loss to Profit QoQ) ■ EBITDA Margin (%): 29.0 (Loss to Profit YoY | Loss to Profit QoQ) ■ PAT: 69.7 (Loss to Profit YoY | Loss to Profit QoQ) ■ EPS (INR): 0.70 (Loss to Profit YoY | Loss to Profit QoQ)
As per attachment.
Others (Uncategorized) · 13 Feb 2026, 11:50 pm
Norris Medicines: Promoter Reclassification Application Closed by BSE Norris Medicines announced its application to reclassify Promoter shareholders to the Public category was closed by BSE on 12 Feb '26. The closure followed an exchange observation regarding non-payment of a disputed penalty. Consequently, the reclassification will not proceed, and the existing shareholding pattern and shareholder classification will remain unchanged. The company stated no further action is pending on this matter.
Norris Medicines Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2026 ,inter alia, to consider and approve As per attachment.
Intimation · 14 Feb 2026, 5:30 am
Norris Medicines Sets Board Meeting for Q3 FY26 Results Norris Medicines Limited (BSE: 524414) has scheduled a Board of Directors meeting on 14th Feb'26 to consider and approve the un-audited financial results for the quarter and nine months ended 31st Dec'25. The company also noted its trading window has been closed for designated persons since 01st Jan'26 and will reopen 48 hours after the financial results are declared to the stock exchange. The meeting will address other business matters as permitted.
As per attachment.
Change in Management · 05 Feb 2026, 12:53 am
Norris Medicines CFO Resigns Citing Personal Reasons Norris Medicines announced the resignation of its Chief Financial Officer (CFO) and Key Managerial Personnel, Mr. Iqubal Patel, effective from the close of business on 03rd Feb'26. The company stated the reason for the departure as "personal reasons." The resignation will be recorded at the next Board Meeting, and the company is currently in the process of appointing a successor.
As per attachment
Change in Management · 12 Dec 2025, 11:27 pm
Norris Medicines: Independent Director and Audit Committee Chair Resigns Norris Medicines Limited (BSE: 524414) announced the resignation of Independent Director Ms. Sathya Venkatachalam (DIN: 06970735), effective 12th Dec'25. She cited personal reasons for her departure. In addition to her board seat, Ms. Venkatachalam has also stepped down from all committees, which included her role as Chairperson of the Audit Committee. The company confirmed there were no other material reasons for the resignation beyond those stated in her letter. This departure creates a key vacancy in board oversight.